Cost-effectiveness of cervical-cancer screening in five developing countries.

BACKGROUND Cervical-cancer screening strategies that involve the use of conventional cytology and require multiple visits have been impractical in developing countries. METHODS We used computer-based models to assess the cost-effectiveness of a variety of cervical-cancer screening strategies in India, Kenya, Peru, South Africa, and Thailand. Primary data were combined with data from the literature to estimate age-specific incidence and mortality rates for cancer and the effectiveness of screening for and treatment of precancerous lesions. We assessed the direct medical, time, and program-related costs of strategies that differed according to screening test, targeted age and frequency, and number of clinic visits required. Single-visit strategies involved the assumption that screening and treatment could be provided in the same day. Outcomes included the lifetime risk of cancer, years of life saved, lifetime costs, and cost-effectiveness ratios (cost per year of life saved). RESULTS The most cost-effective strategies were those that required the fewest visits, resulting in improved follow-up testing and treatment. Screening women once in their lifetime, at the age of 35 years, with a one-visit or two-visit screening strategy involving visual inspection of the cervix with acetic acid or DNA testing for human papillomavirus (HPV) in cervical cell samples, reduced the lifetime risk of cancer by approximately 25 to 36 percent, and cost less than 500 dollars per year of life saved. Relative cancer risk declined by an additional 40 percent with two screenings (at 35 and 40 years of age), resulting in a cost per year of life saved that was less than each country's per capita gross domestic product--a very cost-effective result, according to the Commission on Macroeconomics and Health. CONCLUSIONS Cervical-cancer screening strategies incorporating visual inspection of the cervix with acetic acid or DNA testing for HPV in one or two clinical visits are cost-effective alternatives to conventional three-visit cytology-based screening programs in resource-poor settings.

[1]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[2]  J. Sachs.  Macroeconomics and health: investing in health for economic development , 2002 .

[3]  P. Phillips-Howard,et al.  The cost-effectiveness of permethrin-treated bed nets in an area of intense malaria transmission in western Kenya. , 2003, The American journal of tropical medicine and hygiene.

[4]  D M Parkin,et al.  Visual inspection with acetic acid in the early detection of cervical cancer and precursors , 1999, International journal of cancer.

[5]  T. Wright,et al.  Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. , 2001, JAMA.

[6]  Rob Baltussen,et al.  Programme costs in the economic evaluation of health interventions , 2003, Cost effectiveness and resource allocation : C/E.

[7]  C. Wheeler,et al.  A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.

[8]  T. Wright,et al.  Evaluation of alternative methods of cervical cancer screening for resource‐poor settings , 2000, Cancer.

[9]  Brenda White,et al.  DEPARTMENT OF LABOR , 2006 .

[10]  W. Lawrence,et al.  Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. , 2002, Journal of the National Cancer Institute.

[11]  C. Dye,et al.  Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru , 2002, The Lancet.

[12]  University of ZimbabweJHPIEGO Cervical Cancer Project.  Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting , 1999, The Lancet.

[13]  M. Koopmanschap,et al.  Care and costs for advanced cervical cancer. , 1992, European Journal of Cancer.

[14]  C. Ferreccio,et al.  Effectiveness safety and acceptability of cryotherapy: a systematic literature review. , 2003 .

[15]  R. Aggarwal,et al.  Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. , 2003, Journal of hepatology.

[16]  W. Frable,et al.  Cost-effectiveness of cervical-cancer screening in developing countries. , 2006, The New England journal of medicine.

[17]  T. Wright,et al.  Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. , 2000, Journal of the National Cancer Institute.

[18]  R. Rajkumar,et al.  Effective screening programmes for cervical cancer in low- and middle-income developing countries. , 2001, Bulletin of the World Health Organization.